Skip to content

Significance of Estrogen Status for Muscle Function, Physical Fitness, and Physiological Health Parameters - a Comparison of Age-matched Groups of Women Before and After Menopause.

Effects of Estrogen on Muscle Gain During 12-weeks of Exercise in Post-menopausal Women

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07649356
Acronym
HER-MUSCLEX
Enrollment
30
Registered
2026-06-16
Start date
2026-02-01
Completion date
2027-08-01
Last updated
2026-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Menopause, Muscle Mass and Strength

Keywords

Muslce Mass, Muscle Strength, Menopause, Estrogen, Mitochondria function

Brief summary

As females age and transition through menopause, the decline in oestrogen level profoundly affects skeletal muscle mass and function. HER-MUSCLE aims to unravel the differences in pre and post menopausal women, in regards to muscle size, strength and function. Focusing on postmenopausal females, an increasingly at-risk demographic, HER-MUSCLE addresses a critical gap in understanding how oestrogen influences muscle mass and function. The project involves: 1. Molecular Analysis: Advanced techniques will study the muscle microenvironment, focusing on muscle stem cells (MuSCs), fibro-adipogenic progenitors (FAPs), and other cells critical for muscle regeneration and maintenance. 2. Mitochondrial Function assessed in vivo via magnetic resonance spectroscopy: The impact of oestrogen on mitochondrial health will be examined, exploring how it preserves mitochondrial function and ability to recovery and resist fatigue in response to muscle contractions. Our preliminary data indicate that oestrogen can promote muscle protein synthesis. HER-MUSCLE aims to pave the way for novel therapeutic strategies to manage sarcopenia in postmenopausal women, ultimately leading to better health outcomes and enhanced well-being for this growing population segment.

Detailed description

As females age and transition through menopause, the decline in oestrogen level profoundly affects skeletal muscle mass and function. HER-MUSCLE aims to unravel the differences in pre and post menopausal women, in regards to muscle size, strength and function. Focusing on postmenopausal females, an increasingly at-risk demographic, HER-MUSCLE addresses a critical gap in understanding how oestrogen influences muscle mass and function. The project involves: 1. Molecular Analysis: Advanced techniques will study the muscle microenvironment, focusing on muscle stem cells (MuSCs), fibro-adipogenic progenitors (FAPs), and other cells critical for muscle regeneration and maintenance. 2. Mitochondrial Function assessed in vivo via magnetic resonance spectroscopy: The impact of oestrogen on mitochondrial health will be examined, exploring how it preserves mitochondrial function and ability to recovery and resist fatigue in response to muscle contractions. Our preliminary data indicate that oestrogen can promote muscle protein synthesis. HER-MUSCLE aims to pave the way for novel therapeutic strategies to manage sarcopenia in postmenopausal women, ultimately leading to better health outcomes and enhanced well-being for this growing population segment.

Interventions

None listed

Sponsors

Mette Hansen
Lead SponsorOTHER
Aalborg University
CollaboratorOTHER
University of Copenhagen
CollaboratorOTHER
Aarhus University Hospital
CollaboratorOTHER

Study design

Observational model
OTHER
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
FEMALE
Age
47 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Regular menstrual bleeding (21-35 days cycle). * At least 9 menstrual cycles the last year * Age \>47 years old * BMI 20-30

Exclusion criteria

* Only premenopausal women: Follicular stimulating hormone \> 30 mmol/L * Systematic strength training during the last year (\> 1 strength training session per week) * Systematic high intensity cardiovascular training during the last year (\<2 times per week) * Injuries to the legs which may prevent participation in the physical training program * Magnetizable metals or electrical devices implanted in the body, such as a pacemaker * Use of medication that can influence the effect of immobilization and/or training * Muscular or joint disorders which may affect the results * Metabolic diseases (such as diabetes and cardiovascular diseases) * Previous or present liver or cancer disease * Current or previous thrombosis * Porphyria * Epilepsia * Systemic autoimmune disease * Edema * Smoking or use of other nicotine containing products * Claustrophobia * Addictive behavior, defined as abuse of cannabis, opioids, or other intoxicating substances. * Lack of ability to cooperate * Blood parameters out of normal range at the health check * Blood pressure above 140/90 mmHg

Design outcomes

Primary

MeasureTime frameDescription
Muscle mass1 weekMagnetic resonance imaging

Secondary

MeasureTime frameDescription
Mitochondria Function in vivo measured as phosphocreatine recovery rate1 weeksThe dominant foot will be attached to a pedal mounted on the patient bed and a dedicated 31P surface coil will be secured over the tibialis anterior muscle. The pedal is designed to allow dynamic contractions of the tibialis anterior muscle while changes in metabolites from the tibialis anterior muscle are acquired non-invasively with the 31P coil. Two protocols will be performed: Firstly, 10 repeated contractions (one per 3 sec with a load representing 30% of maximal force) will result in a depletion (30-40%) of phosphocreatine (PCr). The rate constant for PCr recovery over 10 min will be used as an index of in vivo mitochondrial function. Secondly, a total of 80 repeated contractions (one per 3 sec with a load representing 30% of maximal force) will be used to quantify muscle fatigue and concurrent changes in muscle metabolites and intracellular pH (based on the chemical shift between inorganic phosphate and PCr).
Mitochondria Function in vitro measured as maximal oxygen consumption1 weeksAll measurements were performed in duplicate using an Oxygraph-2k (Oroboros, Austria), in hyperoxygenated chambers (250-450 nmol O₂/mL). Respiratory Control Ratio was used to evaluate mitochondrial efficiency. It was calculated as the ratio of maximal ADP-supported respiration (with complex I + II substrates) to leak respiration. Leak respiration reflects oxygen consumption in the absence of ATP synthesis, when only substrates are present and no ADP is added.
Body composition1 weeksDXA
Satelitte cells1 weeksHistochemical Analysis of Muscle tisse
Muscle fiber cross-sectional Area1 weeksHistochemical Analysis of Muscle Tissue
Expression of Muscle proteins1 weeksWestern blotting analysis
FACS Analysis1 weeksFACS analysis to quantify and isolate Muscle satelitte celss, fibro-adipogenic progenitors and macrofages
Muscle Strength1 weeksIncludes measure of leg strength during isometric and dynamic maximal voluntary contractions in a dynamometer (Humac Norm, CSMi, Massachusetts, United States) with a hip angle of 90°. In addition, finger strength, hand grip strength
Functional tests1 weeksIncludes counter-movement jump on a speed force-platform (Swift performance, Australia). To measure dexterity, the nine-hole peg test will be applied.
Cardiovascular fitness1 weekVo2max test on a bike and estimated via Ventriject
Maximal fat oxidation rate1 weekBike test with increasing intensity steps
Resisting metabolic rate1 week
Questionaires1 weekThe participant will be asked to fill out recognized questionnaires about menopause (Menopause Rating Scale), sleep, diet and training readiness (modified version of "The wellbeing review"
Physical Activity Level1 weekAccelerometers
Flexibility1 weeksit-and-reach test
Knee laxity1 weekLachmeter test
Protein expression in adipose tissue1 weekTwo adipose tissue biopsies will be obtained from each participant by a trained physician. Western blotting analysis of expression of proteins related to lipolysis and lipogenesis
Blood pressure1 week
Blood volume1 weekDetermination of blood volume and haemoglobin mass by the carbon-monoxide rebreathing method

Countries

Denmark

Contacts

CONTACTMette Hansen, PhD
mhan@ph.au.dk+4551666551
PRINCIPAL_INVESTIGATORMette Hansen, PhD

Aarhus University, Department of Public Health

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 17, 2026